Invivyd (IVVD) Competitors $0.76 -0.04 (-5.03%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IVVD vs. MCRB, BLUE, KNTE, KRON, CGC, NLTX, VYGR, BTMD, CCCC, and SAGEShould you be buying Invivyd stock or one of its competitors? The main competitors of Invivyd include Seres Therapeutics (MCRB), bluebird bio (BLUE), Kinnate Biopharma (KNTE), Kronos Bio (KRON), Canopy Growth (CGC), Neoleukin Therapeutics (NLTX), Voyager Therapeutics (VYGR), biote (BTMD), C4 Therapeutics (CCCC), and Sage Therapeutics (SAGE). These companies are all part of the "medical" sector. Invivyd vs. Seres Therapeutics bluebird bio Kinnate Biopharma Kronos Bio Canopy Growth Neoleukin Therapeutics Voyager Therapeutics biote C4 Therapeutics Sage Therapeutics Invivyd (NASDAQ:IVVD) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, community ranking, analyst recommendations, earnings, risk, profitability and media sentiment. Do institutionals & insiders hold more shares of IVVD or MCRB? 70.4% of Invivyd shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 17.9% of Invivyd shares are owned by company insiders. Comparatively, 5.1% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts rate IVVD or MCRB? Invivyd presently has a consensus price target of $11.33, indicating a potential upside of 1,400.90%. Seres Therapeutics has a consensus price target of $5.08, indicating a potential upside of 824.75%. Given Invivyd's stronger consensus rating and higher probable upside, equities analysts clearly believe Invivyd is more favorable than Seres Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the MarketBeat Community prefer IVVD or MCRB? Seres Therapeutics received 518 more outperform votes than Invivyd when rated by MarketBeat users. However, 75.00% of users gave Invivyd an outperform vote while only 72.21% of users gave Seres Therapeutics an outperform vote. CompanyUnderperformOutperformInvivydOutperform Votes1275.00% Underperform Votes425.00% Seres TherapeuticsOutperform Votes53072.21% Underperform Votes20427.79% Is IVVD or MCRB more profitable? Seres Therapeutics' return on equity of 0.00% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets InvivydN/A -109.72% -90.91% Seres Therapeutics N/A N/A -55.08% Which has stronger earnings & valuation, IVVD or MCRB? Seres Therapeutics has higher revenue and earnings than Invivyd. Seres Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvivyd$2.26M39.84-$198.64M-$1.96-0.39Seres Therapeutics$126.32M0.74-$113.72M-$0.23-2.39 Which has more volatility & risk, IVVD or MCRB? Invivyd has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.06, meaning that its stock price is 106% more volatile than the S&P 500. Does the media prefer IVVD or MCRB? In the previous week, Invivyd and Invivyd both had 13 articles in the media. Invivyd's average media sentiment score of 0.29 beat Seres Therapeutics' score of 0.18 indicating that Invivyd is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 2 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Seres Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryInvivyd beats Seres Therapeutics on 10 of the 17 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVVD vs. The Competition Export to ExcelMetricInvivydBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.19M$2.91B$5.07B$8.66BDividend YieldN/A1.79%5.10%4.06%P/E Ratio-0.4241.61100.6017.27Price / Sales39.84217.681,195.1369.06Price / CashN/A178.0141.0336.35Price / Book0.474.096.345.87Net Income-$198.64M-$42.42M$119.64M$225.66M7 Day Performance-21.75%-10.63%-5.13%-1.34%1 Month Performance-28.09%-5.81%-2.72%1.15%1 Year Performance-47.56%24.19%31.10%24.02% Invivyd Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVVDInvivyd2.6254 of 5 stars$0.76-5.0%$11.33+1,400.9%-49.7%$90.19M$2.26M-0.42100Short Interest ↑News CoverageGap UpMCRBSeres Therapeutics4.0807 of 5 stars$0.59flatN/A-52.6%$100.45M$126.32M-2.57233Analyst ForecastNews CoverageGap UpBLUEbluebird bio2.8772 of 5 stars$0.36-2.7%N/A-89.4%$72.97M$29.50M-0.16323Upcoming EarningsAnalyst DowngradeNews CoverageKNTEKinnate Biopharma1.3779 of 5 stars$2.65-0.4%N/A+17.3%$125.13MN/A-0.9584High Trading VolumeKRONKronos Bio2.8708 of 5 stars$0.85-3.4%N/A-19.8%$51.31M$8.41M-0.60100Analyst DowngradeNews CoverageGap DownHigh Trading VolumeCGCCanopy Growth1.9561 of 5 stars$3.74-5.1%N/A-29.7%$369.82M$220.27M-0.761,029Short Interest ↓Analyst RevisionNLTXNeoleukin TherapeuticsN/A$39.20-1.2%N/A+162.3%$368.40MN/A-12.6090High Trading VolumeVYGRVoyager Therapeutics4.6688 of 5 stars$6.22-7.0%N/A-13.9%$364.83M$250.01M8.76100Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageBTMDbiote3.4008 of 5 stars$6.57-2.2%N/A+11.1%$364.35M$185.36M25.27194Short Interest ↓Analyst RevisionNews CoverageCCCCC4 Therapeutics2.1453 of 5 stars$4.72-8.0%N/A+136.8%$362.12M$20.76M-2.78150Short Interest ↓SAGESage Therapeutics4.4458 of 5 stars$5.37-6.3%N/A-72.6%$350.52M$86.46M-0.96690Gap Up Related Companies and Tools Related Companies MCRB Competitors BLUE Competitors KNTE Competitors KRON Competitors CGC Competitors NLTX Competitors VYGR Competitors BTMD Competitors CCCC Competitors SAGE Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IVVD) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
